Xinghande Biomedical

SCG Cell Therapy (Xinghande Biomedical) is a clinical-stage biopharmaceutical company specializing in the development of novel immunotherapies for infectious diseases and their associated cancers. The company leverages its proprietary T-cell receptor (TCR) discovery and bispecific antibody platforms to target high-prevalence conditions such as Hepatitis B (HBV), Human Papillomavirus (HPV), and Helicobacter pylori. Its lead program, SCG101, is a first-in-class autologous HBsAg-specific TCR-T cell therapy currently undergoing Phase 1/2 clinical trials for HBV-related hepatocellular carcinoma. With operations spanning Singapore, China, and Germany, SCG integrates R&D, clinical development, and GMP manufacturing to accelerate the delivery of curative cell therapies and biologics to patients globally.